Cardiovascular adverse events in multiple myeloma patients

Markus B. Heckmann, Shirin Doroudgar, Hugo A. Katus, Lorenz H. Lehmann

Research output: Contribution to journalReview articlepeer-review

10 Scopus citations

Abstract

Multiple myeloma is a malignant disease, caused by an uncontrolled clonal proliferation of a specific group of white blood cells, the plasma cells. Clinical manifestations include bone pain due to osteolysis, hypercalcemia, anemia, and renal insufficiency. Proteasome inhibitors have substantially improved survival of patients suffering from multiple myeloma, providing an efficient treatment option mainly for relapsed and refractory multiple myeloma. Although constituting one substance class, bortezomib, carfilzomib, and ixazomib differ greatly regarding their non-hematologic side effects. This article reviews the clinical and preclinical data on approved proteasome inhibitors in an attempt to decipher the underlying pathomechanisms related to cardiovascular adverse events seen in clinical trials.

Original languageEnglish (US)
Pages (from-to)S4296-S4305
JournalJournal of Thoracic Disease
Volume10
DOIs
StatePublished - Dec 1 2018
Externally publishedYes

Keywords

  • Bortezomib
  • Cardio-oncology
  • Cardiotoxicity
  • Carfilzomib
  • Ixazomib
  • Multiple myeloma
  • Proteasome inhibitors

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Fingerprint

Dive into the research topics of 'Cardiovascular adverse events in multiple myeloma patients'. Together they form a unique fingerprint.

Cite this